Doxycycline Capsules, USP, Rx only

/Doxycycline Capsules, USP, Rx only
Doxycycline Capsules, USP, Rx only2018-09-06T09:12:40+00:00

Prescription Drug Name:

Doxycycline Capsules, USP, Rx only

ID:

b42b64bd-caab-440c-9b72-5b80f84e5eb2

Code:

34391-3

DESCRIPTION


id: 5a4297c4-5927-4847-985f-3037b554753c
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Doxycycline is a broad-spectrum antibacterial synthetically derived from oxytetracycline. Doxycycline capsules USP, 50 mg, 75 mg, and 100 mg contain doxycycline monohydrate equivalent to 50 mg, 75 mg, and 100 mg of doxycycline for oral administration. The chemical designation of the light yellow to pale yellow powder is 2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,[4S-(4α,4aα,5α,5aα,6α,12aα)]-,monohydrate. Structural formula: C22H24N2O8 • H2O               M.W. = 462.45      Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. Inert ingredients: colloidal silicon dioxide; magnesium stearate; microcrystalline cellulose; sodium starch glycolate; and a hard gelatin capsule which contains titanium dioxide, FD&C Red # 3, D&C Yellow # 10, gelatin, sodium lauryl sulfate, for the 50 mg strength; iron oxide black, iron oxide red, iron oxide yellow, titanium dioxide, gelatin, sodium lauryl sulfate for the 75 mg strength and  iron oxide black, Iron Oxide Red, Iron Oxide Yellow, Titanium Dioxide, FD & C Red# 3, D&C Yellow # 10, gelatin, sodium lauryl sulfate for the 100 mg strength. The capsules are printed with edible ink containing shellac, titanium dioxide, black iron oxide, red iron oxide and potassium hydroxide for 50 mg, 75 mg and 100 mg strengths.

CLINICAL PHARMACOLOGY


id: b091fbc6-784c-405d-983d-1585573cb2f0
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Doxycycline is virtually completely absorbed after oral administration. Following a 200 mg dose of doxycycline monohydrate, 24 normal adult volunteers averaged the following serum concentration values:

 Time (hr): 0.5  1.0  1.5  2.0  3.0  4.0  8.0  12.0  24.0  48.0  72.0
Conc. 1.02  2.26  2.67  3.01  3.16  3.03  2.03  1.62  0.95  0.37  0.15 (mcg/mL)
Average Observed Values
 Maximum Concentration
             3.61 mcg/mL (± 0.9 sd)
 Time of Maximum Concentration                2.60 hr (± 1.10 sd)
 Elimination Rate Constant           0.049 per hr (± 0.030 sd)
 Half-Life                16.33 hr (± 4.53 sd)
Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may fall as low as 1-5%/72 hours in individuals with severe renal insufficiency (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function. Hemodialysis does not alter serum half-life. Microbiology: Mechanism of Action Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Cross resistance with other tetracyclines is common. Doxycycline has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section of the package insert. Gram-Negative Bacteria Acinetobacter species Bartonella bacilliformis Brucella species Enterobacter aerogenes Escherichia coli Francisella tularensis Haemophilus ducreyi Haemophilus influenzae Klebsiella granulomatis Klebsiella species Neisseria gonorrhoeae Shigella species Vibrio cholerae Vibrio fetus Yersinia pestis Gram-Positive Bacteria Bacillus anthracis  Streptococcus pneumoniae Anaerobes Clostridium species  Fusobacterium fusiforme Propionibacterium acnes Other Bacteria Norcardiae and other aerobic Actinomyces species Borrelia recurrentis Chlamydophila psittaci Chlamydia trachomatis Mycoplasma pneumoniae Rickettsiae Treponema pallidum Treponema pallidum subspecies pertenue Ureaplasma urealyticum Parasites Balantidium coli  Entamoeba species Plasmodium falciparum* *Doxycycline has been found to be active against the asexual erythrocytic forms of Plasmodium falciparum, but not against the gametocytes of P. falciparum. The precise mechanism of action of the drug is not known. Susceptibility Testing Methods: When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drugs used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial. Dilution Techniques: Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method (broth and/or agar).1,2,4,6,7 The MIC values should be interpreted according to the criteria provided in Table 1. Diffusion Techniques  Quantitative methods that require measurement of zone diameters can also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standard test method. 1,3,4 This procedure uses paper disks impregnated with 30 mcg doxycycline to test the susceptibility of bacteria to doxycycline. The disk diffusion interpretive criteria are provided in Table 1. Anaerobic Techniques For anaerobic bacteria, the susceptibility to doxycycline can be determined by a standardized test method5. The MIC values obtained should be interpreted according to the criteria provided in Table 1.
Table 1: Susceptibility Test Interpretive Criteria for Doxycycline and Tetracycline
Bacteria

Minimal 
Inhibitory

Concentration 
(
mcg 
per 
mL
)

Zone 
Diameter 
(
mm
)

Agar 
Dilution 


(
mcg 
per 
mL

S

I

R

S

I

R

S

I

R

Acinetobacter 
spp
.

    Doxycycline ≤4 8 ≥16 ≥13 10 to12 ≤9
    Tetracycline ≤4 8 ≥16 ≥15 12 to14 ≤11
Anaerobes
    Tetracycline ≤4 8 ≥16
Bacillus 
anthracis
    Doxycycline ≤1
    Tetracycline ≤1
Brucella 
species
    Doxycycline ≤1
    Tetracycline ≤1
Enterobacteriaceae

    Doxycycline ≤4   8   ≥16 ≥14 11 to13 ≤10
    Tetracycline ≤4   8   ≥16 ≥15 12 to14 ≤11
Franciscella 
tularensis
    Doxycycline ≤4
    Tetracycline ≤4
Haemophilus 
influenzae

    Tetracycline ≤2 4 ≥8 ≥29 26 to 28 ≤25
Mycoplasma 
pneumoniae
    Tetracycline ≤2
Neisseria 
gonorrhoeae
    Tetracycline ≥38 31 to 37 ≤30 ≤0.25 0.5 to 1 ≥2
Norcardiae and other aerobic
Actinomyces species
  Doxycycline ≤1 2 to 4 ≥8
Streptococcus 
pneumoniae

Doxycycline

≤0.25 0.5 >1 >28 25 to 27 <24
    Tetracycline <1 2 >4 >28 25 to 27 <24
Vibrio 
cholerae

    Doxycycline ≤4 8 ≥16
    Tetracycline ≤4 8 ≥16
Yersinia 
pestis

    Doxycycline ≤4 8 ≥16
    Tetracycline ≤4 8 ≥16
Ureaplasma urealyticum
    Tetracycline ≤1 ≥2
* Organisms susceptible to tetracycline are also considered susceptible to doxycycline. However, some organisms that are intermediate or resistant to
Tetracycline may be susceptible to doxycycline.
† The current absence of resistance isolates precludes defining any results other than “Susceptible”. If isolates yielding MIC results other than susceptible, they
should be submitted to a reference laboratory for further testing.
‡ Gonococci with 30 mcg tetracycline disk zone diameters of  < 19 mm usually indicate a plasmid-mediated tetracycline resistant Neisseria 
gonorrhoeae

isolate. Resistance in these strains should be confirmed by a dilution test (MIC ≥ to 16 mcg / mL).

A report of Susceptible (S) indicates that antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations at the infection site necessary to inhibit growth of the pathogen. A report of Intermediate (I) indicates that the result should be considered equivocal, and, if the bacteria is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug product is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant (R) indicates that the pathogen is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected. Quality Control Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test1,2,3,4,5,6,7. Standard doxycycline and tetracycline powders should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 30 mcg doxycycline disk the criteria in Table 2 should be achieved.
Table 2: Acceptable Quality Control Ranges for Susceptibility Testing for Doxycycline and Tetracycline
QC 
Strain

Minimal 
Inhibitory 
Concentration


(
mcg
/
mL
)

Zone 
Diameter 
(
mm
)

Agar 
Dilution 
(
mcg
/
mL
)

Enterococcus 
faecalis ATCC 29212
    Doxycycline 2 to 8
    Tetracycline 8 to 32
Escherichia 
coli ATCC 25922
    Doxycycline 0.5 to 2 18 to 24
    Tetracycline 0.5 to 2 18 to 25
Eggerthella 
lenta ATCC 43055
    Doxycycline 2 to 16
Haemophilus 
influenzae ATCC 49247
    Tetracycline 4 to 32 14 to 22
Neisseria 
gonorrhoeae ATCC 49226
    Tetracycline 30 to 42 0.25 to 1
Staphylococcus 
aureus ATCC 25923
    Doxycycline 23 to 29
    Tetracycline 24 to 30
Staphylococcus 
aureus ATCC 29213
    Doxycycline 0.12 to 0.5
    Tetracycline 0.12 to 1
Streptococcus 
pneumoniae ATCC 49619
    Doxycycline 0.015 to 0.12 25 to 34
    Tetracycline 0.06 to 0.5 27 to 31
Bacteroides 
fragilis ATCC 25285
    Tetracycline 0.12 to 0.5
Bacteroides 
thetaiotaomicron ATCC 29741
Doxycycline

2 to 8
    Tetracycline 8 to 32
Mycoplasma 
pneumoniae ATCC 29342
    Tetracycline 0.06 to 0.5 0.06 to 0.5
Ureaplasma 
urealyticum ATCC 33175
    Tetracycline ≥8

INDICATIONS AND USAGE


id: a9387b2d-4f3e-4150-93a5-21a47e06080f
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules, USP and other antibacterial drugs, doxycycline capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections:   Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae.   Respiratory tract infections caused by Mycoplasma pneumoniae.   Lymphogranuloma venereum caused by Chlamydia trachomatis.   Psittacosis (ornithosis) caused by Chlamydophila psittaci.   Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence.   Inclusion conjunctivitis caused by Chlamydia trachomatis.   Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis.   Nongonococcal urethritis caused by Ureaplasma urealyticum.   Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms:   Chancroid caused by Haemophilus ducreyi.   Plague due to Yersinia pestis.   Tularemia due to Francisella tularensis.   Cholera caused by Vibrio cholerae.   Campylobacter fetus infections caused by Campylobacter fetus.   Brucellosis due to Brucella species (in conjunction with streptomycin).   Bartonellosis due to Bartonella bacilliformis.   Granuloma inguinale caused by Calymmatobacterium granulomatis. Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:   Escherichia coli   Enterobacter aerogenes   Shigella species   Acinetobacter species   Respiratory tract infections caused by Haemophilus influenzae.   Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:   Upper respiratory infections caused by Streptococcus pneumoniae.   Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to   aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative  in the treatment of the following infections:   Uncomplicated gonorrhea caused by Neisseria gonorrhoeae.   Syphilis caused by Treponema pallidum.   Yaws caused by Treponema pertenue.   Listeriosis due to Listeria monocytogenes.   Vincent’s infection caused by Fusobacterium fusiforme.   Actinomycosis caused by Actinomyces israelii.   Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy.

CONTRAINDICATIONS


id: c1dd2866-d718-48bc-b1d7-1ce522d01e57
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines.

WARNINGS


id: d974f0ba-edb0-4bc0-876f-8d70b9cef023
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP, EXCEPT FOR ANTHRAX, INCLUDING INHALATIONAL ANTHRAX (POST- EXPOSURE), UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline capsules, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus. The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function. Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

PRECAUTIONS


id: ea753091-bce5-4e7f-b388-4ec38c6ab423
displayName: PRECAUTIONS SECTION
FDA Article Code: 42232-9

General: As with other antibacterial preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, the antibiotic should be discontinued and appropriate therapy instituted. Intracranial hypertension (IH, pseudotumorcerebri) has been associated with the use of tetracyclines including doxycycline.Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and doxycyline should be avoided because isotretinoin is also known to cause pseudotumorcerebri. Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize. Incision and drainage or other surgical procedures should be performed in conjunction with antibacterial therapy when indicated. Prescribing doxycycline capsules in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Information for Patients: All patients taking doxycycline should be advised: –to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (e.g., skin eruptions, etc.) occurs. Sunscreen or sunblock should be considered. (See WARNINGS.) –to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration.(See ADVERSE REACTIONS.) –that the absorption of tetracyclines is reduced when taken with foods, especially those which contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. (See Drug Interactions.) –that the absorption of tetracyclines is reduced when taking bismuth subsalicylate. (See Drug Interactions.) –not to use outdated or poorly stored doxycycline. –that the use of doxycycline might increase the incidence of vaginal candidiasis. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. Patients should be counseled that antibacterial drugs including doxycycline capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When doxycycline capsules are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by doxycycline capsules or other antibacterial drugs in the future. Laboratory Tests: In venereal disease when coexistent syphilis is suspected, a dark-field examination should be done before treatment is started and the blood serology repeated monthly for at least four months. In long-term therapy, periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic studies should be performed. Drug Interactions: Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations. Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline. The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. Concurrent use of tetracycline may render oral contraceptives less effective. Drug/Laboratory Test Interactions: False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test. Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate the carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with related antibacterial, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in in vitro mammalian cell assays have been reported for related antibacterial (tetracycline, oxytetracycline). Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied. Pregnancy: Teratogenic Effects. Pregnancy Category D: There are no adequate and well-controlled studies on the use of doxycycline in pregnant short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS – the Teratogen Information System – concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk.8 A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. (Sixty-three [0.19%] of the controls and 56 [0.30%] of the cases were treated with doxycycline.) This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation) with the exception of a marginal relationship with neural tube defect based on only two exposed cases.9 A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age.10 Labor and Delivery: The effect of tetracyclines on labor and delivery is unknown Nursing Mothers: Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines, including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated; however, the effects of prolonged exposure to doxycycline in breast milk are unknown.11 Because of the potential for adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See WARNINGS.) Pediatric Use: See WARNINGS and DOSAGE AND ADMINISTRATION sections.

ADVERSE REACTIONS


id: 816637d1-6332-4d0f-86b9-527b27652039
displayName: ADVERSE REACTIONS SECTION
FDA Article Code: 34084-4

Due to oral doxycycline’s virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines. Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See DOSAGE AND ADMINISTRATION.) Skin: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme have been reported. Exfoliative dermatitis has been reported but is uncommon. Photosensitivity is discussed above. (See WARNINGS.) Renal Toxicity: Rise in BUN has been reported and is apparently dose related. (See WARNINGS.) Hypersensitivity Reactions: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoidpurpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus. Blood: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported with tetracyclines. Other: Intracranial hypertension (IH, pseudotumorcerebri) has been associated with the use of tetracyclines. (See PRECAUTIONS-General.) When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function are known to occur.

OVERDOSAGE


id: 1606b7c1-7b05-4652-913c-14dac2664bc9
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life, and it would not be of benefit in treating cases of overdosage.

DOSAGE AND ADMINISTRATION


id: 30b6c3b4-539f-494f-990d-3026bcbcd253
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS. Adults: The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours or 50 mg every 6 hours) followed by a maintenance dose of 100 mg/day. The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended. For pediatric patients above eight years of age: The recommended dosage schedule for pediatric patients weighing 100 pounds or less is 2 mg/lb of body weight divided into two doses on the first day of treatment, followed by 1 mg/lb of body weight given as a single daily dose or divided into two doses, on subsequent days. For more severe infections up to 2 mg/lb of body weight may be used. For pediatric patients over 100 pounds the usual adult dose should be used. Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice a day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose. Acute epididymo-orchitis caused by 
N.
 
gonorrhoeae:
100 mg, by mouth, twice a day for at least 10 days.
Primary and secondary syphilis: 300 mg a day in divided doses for at least 10 days. Uncomplicated urethral, endocervical, or rectal infection in adults caused by 
Chlamydia
 
trachomatis:
100 mg, by mouth, twice a day for at least 7 days.
Nongonococcal urethritis caused by 
C.
 
trachomatis
 and 
U.
 
urealyticum:
100 mg, by mouth, twice a day for at least 7 days.
Acute epididymo-orchitis caused by 
C.
 
trachomatis:
100 mg, by mouth, twice a day for at least 10 days.
Inhalational anthrax (post-exposure): ADULTS: 100 mg of doxycycline, by mouth, twice a day for 60 days. CHILDREN: weighing less than 100 pounds (45 kg); 1 mg/lb (2.2 mg/kg) of body weight, by mouth, twice a day for 60 days. Children weighing 100 pounds or more should receive the adult dose. When used in streptococcal infections, therapy should be continued for 10 days. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.) If gastric irritation occurs, doxycycline may be given with food. Ingestion of a high fat meal has been shown to delay the time to peak plasma concentrations by an average of one hour and 20 minutes. However, in the same study, food enhanced the average peak concentration by 7.5% and the area under the curve by 5.7%.

HOW SUPPLIED


id: 816433ba-b519-4b0e-86cf-440bb730d530
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Doxycycline Capsules, USP 50 mg have a yellow opaque cap and a white opaque body. The capsules are imprinted  “NL 790”  with white ink on the cap and “50 mg”  with brown ink on the body, filled with yellow to beige powder. Each capsule contains doxycycline monohydrate equivalent to 50 mg doxycycline. Doxycycline Capsules, USP 50 mg is available in:     Bottles of 50 capsules ……………………….NDC 40032-790-11     Bottles of 100 capsules ………………………NDC 40032-790-01    Bottles of 1000 capsules ……………………..NDC 40032-790-10 Doxycycline Capsules, USP 75 mg have a brown opaque cap and a white opaque body. The capsules are imprinted  “NL 791”  with white ink on the cap and “75 mg”  with brown ink on the body, filled with yellow to beige powder. Each capsule contains doxycycline monohydrate equivalent to 75 mg doxycycline. Doxycycline Capsules, USP 75 mg is available in:      Bottles of 50 capsules …………………………NDC 40032-791-11     Bottles of 100 capsules ………………………..NDC 40032-791-01    Bottles of 1000 capsules ………………………NDC 40032-791-10 Doxycycline Capsules, USP 100 mg have a brown opaque cap and a yellow opaque body. The capsules are imprinted  “NL 792”  with white ink on the cap and “100 mg”  with brown ink on the body, filled with yellow to beige powder. Each capsule contains doxycycline monohydrate equivalent to 100 mg doxycycline. Doxycycline Capsules, USP 100 mg is available in:      Bottles of 50 capsules ………………………..NDC 40032-792-11     Bottles of 250 capsules…………………………NDC 40032-792-02    Bottles of 1000 capsules ……………………….NDC 40032-792-10 STORE AT 20° to 25°C (68° to 77°F). [SEE USP CONTROLLED ROOM TEMPERATURE.] DISPENSE IN A TIGHT, LIGHT-RESISTANT CONTAINER AS DEFINEDIN THE USP/NF. PROTECT FROM LIGHT.

ANIMAL PHARMACOLOGY AND OR TOXICOLOGY


id: 29287bd8-73e7-4fbf-9d0d-c277da0e9e6b
displayName: ANIMAL PHARMACOLOGY & OR TOXICOLOGY SECTION
FDA Article Code: 34091-9

Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO4, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO4, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline. Minocycline, tetracycline PO4, methacycline, doxycycline, tetracycline base, oxytetracyclineHCl and tetracycline HCl were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet. Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline), in chickens (chlortetracycline) and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.

REFERENCES


id: cc436f2c-e904-4bb4-9aec-9c8730606009
displayName: REFERENCES SECTION
FDA Article Code: 34093-5

1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twentyfifth Informational Supplement, CLSI document M100-S25. Clinical and Laboratory Standards Institute, 950 West Valley Road,Suite 2500, Wayne, Pennsylvania 19087, USA, 2015. 2. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – 10th ed. CLSI document M07- A10. Clinical and Laboratory Standards Institute, 950 WestValley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015. 3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard  11th ed. CLSI document M02-A12. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500,Wayne, Pennsylvania 19087, USA, 2015. 4. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Approved Guideline—Second Edition. CLSI document M45-A2. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2010. 5. Clinical and Laboratory Standards Institute (CLSI). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard  Eighth Edition. CLSI document M11-A8. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087 USA, 2012. 6. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard—Second Edition.CLSI document M24-A2. Clinical and Laboratory Standards Institute, 950West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA. 2011. 7. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing for Human Mycoplasmas; Approved Guideline.CLSI document M43-A. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500,Wayne, Pennsylvania 19087, USA. 2011. Rx only Manufactured by: Novel Laboratories, Inc. 400 Campus Drive Somerset, NJ0887 PI7920000103 Revised: 09/2015

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


id: ed63cf2c-f894-4192-bfed-37d885d1fdc4
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

Doxycycline Capsules, USP 50 mg 50 count Doxycycline Capsules, USP 75 mg 100 count Doxycycline Capsules, USP 100 mg 1000 count